Use of bacterial phage associated lysing enzymes for treating streptococcal infections of the upper respiratory tract
US6326002A · kind A · utility
29Cited by
6References
14Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 28, 2000 |
| Grant date | Dec 4, 2001 |
| Priority date | — |
| Expiry date | Sep 28, 2020 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Y302/01017
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention discloses a method for treating Streptococcal infections of the upper respiratory tract, comprising administering an effective amount of a lysin enzyme produced by group C Streptococcal bacteria infected with a C1 bacteriophage specific for the bacteria to a mouth, throat, or nasal passage of a mammal, the method providing a concentration of from about 100 to 500,000 active enzyme units per milliliter of fluid in the environment of said nasal or oral passages.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.